Is this Healthcare ASX stock worth buying right now?
Not every ASX stock with falling profit is a bad business. Sometimes profits fall because companies invest, restructure or write off assets for future growth. CSL Limited is one such ASX stock where the short-term numbers look weak but the long-term story may still be strong.
CSL Limited (ASX: CSL)
is a well-known healthcare company listed on Australian stock market and over the years it has established itself as a leading global biotechnology and plasma therapies firm. This ASX stock runs companies such as CSL Behring, CSL Seqirus and CSL Vifor which specialize in rare diseases, vaccines and treatments for iron deficiency. It remains committed to significant investments in the research, innovation and production capabilities to ensure the sustained long-term growth.
It released its half year results period ending 31 December 2025 on 11 February 2026. CSL recorded revenue of approximately US$8.3 billion which is a slight decrease from the prior year.
The reported net profit after tax dropped significantly to approximately US$401 million because of the restructuring expenses and asset impairments although underlying profit stayed much more stable at around US$1.9 billion. This indicates that the main business performance remains fairly stable despite the impact of one-time items on reported profits.
CSL is also implementing transformation efforts aimed at streamlining operations, cutting expenses and enhancing efficiency. It has already reached a large part of its intended cost reductions and is focusing investments on growth areas such as increasing plasma manufacturing capacity in the United States.
It has also entered into a licensing agreement with Eli Lilly for a drug called clazakizumab where CSL will retain exclusive rights for certain cardiovascular treatments while also receiving upfront and milestone payments. This partnership highlights the company’s continued focus on innovation and new therapies which could support future revenue growth.
CSL Limited remains a strong healthcare ASX stock with stable underlying earnings, ongoing investments in innovation and long-term growth opportunities driven by its biotechnology and vaccine businesses.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
